| Literature DB >> 27403126 |
Imane Bennani1, Raphael Lopez2, Delphine Bonnet3, Gregoire Prevot4, Arnaud Constantin5, Dominique Chauveau6, Carle Paul1, Cristina Bulai Livideanu1.
Abstract
Limited mouth opening (LMO) is a frequent complication of systemic sclerosis (SS). Its management is complex and there are limited treatment options. We report four patients with SS and severe LMO [interincisal distance (IID) <30 mm] treated with pulsed carbon dioxide (CO2) laser. Pulsed CO2 laser treatment of the white lips was performed after all patients had signed a written informed consent in the absence of alternative treatment. Treatment was carried out under locoregional anaesthesia using a Sharplan 30C CO2 laser in the Silk Touch® resurfacing mode. One to three laser sessions were performed at intervals of 8-12 months between sessions. Assessments were performed at 3 and 12 months with measurement of the IID using a ruler, calculation of the Mouth Handicap in Systemic Sclerosis (MHISS) scale and global evaluation by the patients. Adverse events were also reported. In all four patients, an improvement in IID occurred 3 months after the first session with a mean gain of +5 mm (range: 2-7). At 12 months, a mean gain of +8.5 mm (range: 7-10) in IID was observed. The MHISS score decreased by a mean of •14 (range: 11-17). All patients showed improvement of lip flexibility or mouth opening, allowing better phonation and mastication and easier dental care. Adverse effects were transient erythema and/or dyschromia. CO2 laser appears to be effective and well tolerated in the improvement of LMO in SS.Entities:
Keywords: Carbon dioxide laser; Interincisal distance; Limited mouth opening; Microstomia; Mouth Handicap in Systemic Sclerosis scale; Systemic sclerosis
Year: 2016 PMID: 27403126 PMCID: PMC4924459 DOI: 10.1159/000445821
Source DB: PubMed Journal: Case Rep Dermatol ISSN: 1662-6567
Fig. 1Immediate appearance after pulsed CO2 laser treatment in patient 4.
Fig. 2First and second patients. a Mouth opening before CO2 laser treatment in the first patient. b Mouth opening after the last evaluation in the first patient. c Mouth opening before CO2 laser treatment in the second patient. d Mouth opening after the last evaluation in the second patient.
Fig. 3Third and fourth patients. a Mouth opening before CO2 laser treatment in the third patient. b Mouth opening after the last evaluation in the third patient. c Mouth opening before CO2 laser treatment in the fourth patient. d Mouth opening after the last evaluation in the fourth patient.
Demographic, clinical and therapeutic characteristics of patients
| Patient characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Sex | female | female | female | female |
| Age, years | 57 | 63 | 43 | 45 |
| Phototype | 4 | 2 | 3 | 2 |
| Type of SS | dSS | CREST syndrome | dSS | scleromyositis |
| Year of diagnosis | 2007 | 1990 | 2008 | 1996 |
| Modified Rodnan score (0–51) | 17 | 18 | 12 | 15 |
| Concurrent systemic disease | none | high blood pressure | none | none |
| Concurrent medications | nifedipine extended-release 30 mg/day | omeprazole 20 mg/day, alendronate 70 mg/month, irbesartan/hydrochloro-thiazide 150/12.5 mg/day, amlodipine 5 mg/day | nicardipine 20 mg/day, hydroxy-chloroquine 200 mg/day, bosentan 125 mg × 2/day, 6 months/year iloprost infusion 0.5–1 ng/kg/min (6 h per day, for 5 days every 6–8 weeks), 6 months/year | diltiazem 60 mg × 2/day |
| Dates of CO2 laser sessions | S1: 01/2012 | S1: 04/2013 | S1:01/2014 | S1:01/2014 |
| S2: 11/2012 | S2: 12/2013 | S2: 11/2014 | ||
| S3: 11/2013 | ||||
| IID, mm | initial: 29 | Initial: 17 | initial: 26 | initial: 25 |
| S1, M3: 34 | S1, M3: 24 | S1, M3: 32 | S1, M3: 27 | |
| S2, M3: 35 | S2, M3: 25 | S1, M12: 35 | S2, M3: 30 | |
| S3, M3: ND | S2, M12: 27 | S2, M12: 33 | ||
| S3, M12: 36 | ||||
| final gain: +7 | final gain: +10 | final gain: +9 | final gain: +8 | |
| (24.1%) | (58.8%) | (34.6%) | (32%) | |
| MHISS (0–48) | ND | initial: 44 | initial: 31 | initial: 42 |
| final: 30 | final: 14 | final: 31 | ||
| Patient global assessment of treatment response (–1, 0, +1) | +1 | +1 | +1 | +1 |
| Open question to patients: ‘What is improved by this treatment?’ | lip flexibility and easier dental care | lip flexibility and mouth opening with better phonation and mastication and easier dental care | mouth opening with better mastication and easier dental care | lip flexibility with better phonation and mastication and easier dental care |
| Adverse events (duration in days) | erythema: 15 | erythema: 15 | erythema: 15 | erythema: 15 |
| pigmentation: 90 | pigmentation: 90 | hypochromia: 90 | ||
dSS = Diffuse systemic scleroderma; S = session; M = month; ND = not done.